EX-23.1 6 ex_895116.htm EXHIBIT 23.1

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

| 1) | Registration Statement (Form S-3 No. 333-291489) and related Prospectus of Registrant,

| 2) | Registration Statement (Form S-8 No. 333-265540) pertaining to the 2018 Omnibus Incentive Plan of Registrant,

| 3) | Registration Statement (Form S-8 No. 333-168390) pertaining to the 2000 Employee Stock Purchase Plan of Registrant,

| 4) | Registration Statement (Form S-8 No. 333-225708) pertaining to the 2018 Omnibus Incentive Plan of Registrant,

| 5) | Registration Statement (Form S-8 No. 333-147336) pertaining to the 2000 Employee Stock Purchase Plan of Registrant, and

| 6) | Registration Statement (Form S-8 No. 333-152676) pertaining to the 2008 Equity Incentive Plan of Registrant;

of our report dated March 12, 2026, with respect to the consolidated financial statements of Filana Therapeutics, Inc. (formerly known as “Cassava Sciences, Inc.”) included in this Annual Report (Form 10-K) of Filana Therapeutics, Inc. for the year ended December 31, 2025.

/s/ Ernst &Young LLP

Austin, Texas

March 12, 2026